ERBB2 and non-small cell lung carcinoma: Studies paring paclitaxel or docetaxel with YM155 did not show added benefit for YM155 as a co-therapy in melanoma [85], human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer [86] and non-small-cell lung cancer [87].